Cyteir Therapeutics announced the promotion of David Gaiero to Chief Financial Officer CFO, David was previously Vice President of Finance at Cyteir. As CFO, David will continue to manage the finance department, to oversee the company’s overall financial operations, and to help drive the long-term business and financial strategy of Cyteir, reporting directly to the President & CEO.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CYT:
- Cyteir downgraded to Underweight from Equal Weight at Morgan Stanley
- Cyteir Therapeutics downgraded to Neutral at BofA after strategic prioritization
- Cyteir Therapeutics downgraded to Neutral from Buy at BofA
- Cyteir Therapeutics downgraded to Neutral from Overweight at JPMorgan
- Cyteir Therapeutics announces prioritization of CYT-0851 development